DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2841 | Jnj-40264796 | Negative control for JNJ-40068782 |
|
| DCC2842 | JNJ-40355003 Featured | JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor. |
|
| DCC2843 | Jnj-40573663 | Negaive control for JNJ-42396302 |
|
| DCC2844 | Jnj-40929837 | Novel potent, orally active LTA4H inhibitor |
|
| DCC2845 | Jnj-42396302 | Novel inhibitor of PDE10A |
|
| DCC2846 | Jnj-42491293 | Novel ago-PAM for the metabotropic glutamate receptor subtype 2 (mGluR2) |
|
| DCC2847 | Jnj-49153390 | Novel inhibitor of respiratory syncytial virus (RSV), binding the RSV F glycoprotein and inhibiting membrane fusion |
|
| DCC2848 | Jnj-53721590 | Negative control for JNJ-54119936 |
|
| DCC2849 | Jnj-61432059 | Novel TARP γ-8 Selective AMPAR Negative Modulator |
|
| DCC2850 | Jnj-dgat1-a | Selective DGAT1 inhibitor |
|
| DCC2851 | Jnj-dgat2-b | Selective DGAT2 inhibitor |
|
| DCC2852 | Jns 1-40 | Novel cysteine-reactive covalent ligand, selectively targeting C377 of PPP2R1A to impair breast cancer signaling, proliferation, and in vivo tumor growth |
|
| DCC2853 | Jp1201 | Novel SMAC mimetic, sensitizing non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner |
|
| DCC2854 | Jp4-039 | Non-toxic radioprotector GS-nitroxide, improving hematopoiesis in long-term bone marrow cultures (LTBMCs) |
|
| DCC2855 | Jr-220 | Non-toxic anti-relapse agent, acamprosate |
|
| DCC2856 | Jra-003 | Novel selective inhibitor of nuclear translocation of IKKα as the most potent synthetic gibberellin against cancer-derived cell lines, displaying no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC) |
|
| DCC2857 | Jrc-ii-191 | Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor |
|
| DCC2858 | Js399-19 | Novel specific inhibitor of Fusarium myosin I; Fungicide |
|
| DCC2859 | Jsf-2019 | Novel antitubercular agent, inhibiting InhA and FAS-II pathway |
|
| DCC2860 | Jsf-2513 | Novel potent antitubercular agent, inhibiting InhA and FAS-II pathway |
|
| DCC2861 | Jsi287 | Novel ERK inhibitor, alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway |
|
| DCC2862 | Jte-151 | Novel RORγ |
|
| DCC2863 | Jte-607 | Cytokine release inhibitor, inhibiting production of IL-1ß, IL-8, IL-6, IL-10 and TNFalpha |
|
| DCC2864 | Jtk-853 | Novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase |
|
| DCC2865 | Jts-653 | Novel orally active and selective transient receptor potential vanilloid 1 (TRPV1) antagonist |
|
| DCC2866 | Jtt-552 | Novel inhibitor of urate transporter 1 (URAT1) |
|
| DCC2867 | jtv-506 | Novel K(ATP) channel opener |
|
| DCC2868 | Jtv-803 Mesylate | Specific inhibitor of factor Xa |
|
| DCC2869 | Julolidine Phenoxazone Azide | Novel live-cell peobe of voltage-dependent structural changes of voltage-gated Kv2.1 channels |
|
| DCC2870 | jwb1-84-1 Trihydrochloride | Novel neuroprotective agent, improving cognitive performances in a transgenic mouse model of AD |
|
